首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 140 毫秒
1.
目的 观察肝癌缺失基因1(DLC-1)对HT-29细胞侵袭能力的影响.方法 用脂质体法将重组质粒pcDNA3.1-DLC-1转染HT-29细胞;应用Rho激酶(ROCK)特异性抑制剂Y27632处理HT-29细胞;Western blot检测p-MLC蛋白表达;Transwell小室实验检测细胞侵袭能力.结果 野生型HT-29细胞DLC-1基因表达呈阴性,经转染获得DLC-1稳定表达细胞系;与对照组及空载组HT-29细胞相比,转染组和ROCK抑制剂组p-MLC蛋白表达均下调,细胞侵袭能力受到抑制(P<0.05).结论 转染DLC-1基因可能通过抑制ROCK活性,从而抑制HT-29细胞的侵袭能力.  相似文献   

2.
目的研究甘油二酯激酶(DGK)的抑制剂R59022对心肌细胞自噬及内皮素1(ET-1)诱导的心肌肥大的影响,并探讨其可能机制。方法原代培养乳鼠心肌细胞,ET-1诱导乳鼠心肌细胞肥大;Western blot法检测自噬相关蛋白微管相关蛋白1轻链3(LC3)、beclin-1、p62的表达以及Akt的磷酸化及非磷酸化蛋白表达;RT-PCR技术检测心肌肥大基因脑钠肽(BNP)、β-肌球蛋白重链(β-MHC)的mRNA表达水平;细胞免疫荧光检测心肌细胞表面积。结果 ET-1作用乳鼠心肌细胞24 h明显促进心肌细胞肥大,并诱导自噬相关蛋白LC3-Ⅱ/Ⅰ、beclin-1的表达增强,p62表达减弱。自噬抑制剂氯喹(CQ)、3-甲基腺嘌呤(3-MIA)减小心肌细胞表面积,下调肥大基因BNP、β-MHC的mRNA表达,改善ET-1诱导的心肌细胞肥大,而自噬激动剂雷帕霉素(RAPA)则促进ET-1诱导心肌细胞肥大;R59022预处理增加ET-1诱导的LC3-Ⅱ/Ⅰ、beclin-1的表达,增强ET-1诱导的心肌细胞自噬,同时进一步促进ET-1诱导的心肌细胞表面积的增大,BNP、β-MHC的mRNA表达水平的增加,促进ET-1诱导的心肌细胞肥大;对Akt表达的结果显示,ET-1明显下调Akt的磷酸化水平,R59022对此有促进作用。结论 R59022增强ET-1诱导的心肌细胞自噬,促进心肌细胞肥大,其机制可能与抑制Akt的激活,从而抑制mTOR通路的活化有关。  相似文献   

3.
《中南药学》2020,(2):194-199
目的在体外培养的大鼠胸主动脉平滑肌细胞(VSMCs)模型上,观察钠/氢交换蛋白1(NHE1)选择性抑制剂cariporide对糖基化终末产物(AGEs)诱导VSMCs表型转化的作用并探讨相关机制。方法采用CCK8检测VSMCs细胞增殖,Transwell试验检测细胞迁移情况;BCECF荧光探针检测细胞内pH值及NHE1活性;Western blot检测NHE1、α-SMA、SM22α及OPN蛋白表达。结果 NHE1选择性抑制剂cariporide及Rho激酶(ROCK)抑制剂Y-27632可显著拮抗AGEs诱导的VSMCsα-SMA、SM22α蛋白表达降低及OPN蛋白表达的增多,抑制VSMCs转换为合成表型(去分化表型),从而抑制AGEs诱导的VSMCs的增殖和迁移;同时Y-27632可显著抑制AGEs诱导的细胞内pH值升高,NHE1的活性及蛋白表达。结论该研究结果提示NHE1活化在AGEs诱导VSMCs表型转化中可能起重要作用,同时AGEs调节NHE1活化的机制可能与ROCK相关。  相似文献   

4.
目的:探讨内皮素-1是否通过细胞周期蛋白质D1与细胞外调节蛋白激酶通路促进人脐动脉平滑肌细胞增殖。方法:采用MTT法观察ET-1和PD98059对人脐动脉平滑肌细胞生长的作用;[~3H]TdR法观察对细胞DNA合成的作用;流式细胞仪法观察对细胞增殖周期的影响;蛋白质印迹法观察对细胞外调节蛋白激酶和细胞周期蛋白质D1表达的影响。结果:首先,同没有ET-1组和PD98059组比较,ET-1促进平滑肌细胞增殖(P<0.05)。PD98059抑制ET-1诱导的血管平滑肌细胞增殖。第二,与没有ET-1组比较,ET-1促进平滑肌细胞DNA合成(P<0.05)。第三,ET-1促进平滑肌细胞增殖周期从G_0/G_1期向S期的转变,与没有ET-1组比较,G_0/G_1期细胞百分比明显减少,S期细胞百分比明显增加(P<0.05)。第四,ET-1增加细胞外信号调节性激酶的磷酸化水平和细胞周期蛋白质D1的蛋白表达,ERK的抑制剂可以抑制细胞外信号调节性激酶的磷酸化水平和细胞周期蛋白质D1的蛋白表达,与没有ET-1组比较,磷酸化-ERK和细胞周期蛋白质D1表达明显增强,对非磷酸化ERK表达没有影响。结论:内皮素-1可以通过细胞周期调节素D1与细胞外信号调节性激酶通路促进平滑肌细胞增殖。  相似文献   

5.
目的探究JTE-013通过RhoA/ROCK1/Drp1通路调控线粒体损伤和凋亡对过敏性鼻炎(allergic rhinitis,AR)保护作用及机制。方法用卵清蛋白(OVA)建立小鼠AR模型。造模结束后,记录揉鼻、打喷嚏的次数。然后鼻组织切片进行HE、TUNEL和DHE染色。在体外,通过人重组白细胞介素-13(IL-13)刺激人鼻黏膜上皮细胞(HNEpCs),Western blot法检测JTE-013和Y27632对RhoA、ROCK1、Drp1及其相关磷酸化的蛋白和细胞凋亡相关蛋白表达影响。免疫荧光观察JTE-013和Y27632对细胞总ROS、线粒体膜电位和线粒体ROS生成,Drp1易位情况以及Cyt-c的表达情况。结果JTE-013减少了AR小鼠的揉鼻和打喷嚏频率,减轻鼻黏膜增厚并降低嗜酸细胞浸润。TUNEL和DHE染色结果提示,JTE-013可以抑制小鼠鼻上皮细胞凋亡并减少ROS表达。Western blot结果表明,JTE-013和Y27632都能明显降低RhoA、ROCK1、Drp1及p-Drp1(616),抑制凋亡蛋白Bax、cleaved-caspase-3、Cyt-c、cleaved-caspase-9表达并上调了p-Drp1(637)、Bcl-2表达。免疫荧光显示JTE-013或ROCK1的抑制剂几乎阻断了IL-13介导鼻黏膜上皮细胞ROS和mtROS生成增加、抑制了线粒体膜电位降低,阻滞了Cyt-c表达和Drp1易位。结论JTE-013能够通过抑制RhoA/ROCK1/Drp1信号轴调节线粒体的形态和功能,从而缓解AR小鼠鼻黏膜上皮细胞炎症。  相似文献   

6.
目的探究小干扰RNA对人卵巢癌细胞株CXCR4基因表达和侵袭力的影响。方法利用单细胞克隆技术从人卵巢癌细胞系SW626中分离培养细胞株CXCR4,并设计合成针对CXCR4基因的小干扰RNA,在脂质体介导下,重组表达质粒转染人卵巢癌细胞株,利用RT-PCR方法对CXCR4基因表达进行检查,观察转染后细胞株的侵袭能力。实验细胞分为不做处理的空白对照组、转染空病毒载体的阴性对照组、siRNA组。结果 siRNA组的CXCR4 CXCR4 mRNA水平、蛋白表达率、穿膜细胞数均明显低于空白对照组和阴性对照组(P<0.05),而空白对照组与阴性对照组之间无明显差异(P>0.05)。结论小干扰RNA可有效抑制人卵巢癌细胞株CXCR4基因表达和侵袭力。  相似文献   

7.
目的观察干扰ROCK1基因对鼻咽癌的细胞侵袭影响。方法 收集2016年1—12月临沂市河东区人民医院30例鼻咽癌病人临床鼻咽癌标本及同期鼻咽癌的癌旁组织,通过免疫组织化学法(免疫组化)检测ROCK1的表达;培养鼻咽癌细胞株6-10B和永生化的鼻咽上皮细胞NP69,蛋白质印迹法(Western Blot)方法检测ROCK1的表达;使用ROCK1的抑制剂Y-27632处理6-10B细胞株,通过Transwell小室实验,检测鼻咽癌的细胞侵袭。结果 免疫组化结果显示,30例鼻咽癌组织中,ROCK1有18例阳性,12例阴性;而对照组中只有2例阳性,鼻咽癌组的ROCK1明显高表达,与对照组相比差异有统计学意义(χ2 =19.20,P<0.000 1);Western Blot检测结果显示,6-10B组的ROCK1表达明显高于NP69细胞组;侵袭实验结果显示,未处理组为(171.67±17.89),明显高于10 μM组(120±19.07)和30 μM组(67.33±13.58),差异有统计学意义(P<0.05)。结论 ROCK1基因与鼻咽癌的细胞侵袭有关。  相似文献   

8.
目的探讨重组人红细胞生成素(rh EPO)对高糖诱导的正常人肾小管上皮(HK-2)细胞增殖及凋亡的影响及其可能机制。方法将体外培养的HK-2细胞按随机数字表法分为空白对照组、高糖诱导组(高糖终浓度为30mmol/L)、甘露醇对照组(甘露醇浓度为24.5 mmol/L)、rh EPO对照组(rh EPO终浓度为20 U/m L)、不同浓度rh EPO干预组(高糖终浓度为30 mmol/L+rh EPO终浓度分别为5、10、20 U/m L)及Rho激酶抑制剂(Y27632)组(Y27632终浓度为30μmol/L+高糖终浓度为30 mmol/L),各组均刺激24 h。应用RT-PCR法检测各组HK-2细胞Rho A、ROCK1 m RNA的表达;MTT法测定细胞增殖,流式细胞技术分析细胞凋亡。结果高糖诱导组Rho A及ROCK1m RNA表达较空白对照组显著升高(P<0.05),不同浓度rh EPO干预组Rho A m RNA及ROCK1 m RNA的表达较高糖诱导组显著减少(P<0.05),高糖诱导组及不同浓度rh EPO干预组Rho A m RNA与ROCK1 m RNA表达呈正相关。rh EPO可明显促进HK-2细胞增殖(P<0.05),而高糖可诱导正常人肾小管上皮细胞凋亡,加入不同浓度rh EPO或Y27632干预后,其凋亡明显受抑制(P<0.05),且在实验rh EPO浓度范围内,rh EPO促进增殖及抑制凋亡的作用呈现浓度依赖性。结论 rh EPO可促进高糖诱导的HK-2细胞增殖,抑制高糖诱导的HK-2细胞凋亡,其机制可能与阻断Rho A/ROCK信号通路有关。  相似文献   

9.
目的 构建表达CD2AP基因转录起始位点上游启动子的表达质粒,转染人类胚胎肾(HEK)-293T细胞,评价其启动子活性.方法 以人全血细胞总DNA为模板,PCR扩增CD2AP转录起始位点上游2082 bp的启动子区片段.亚克隆此片段至无启动子活性的pGL-3基本载体荧光素酶报告基因上游的多克降位点,构建含CD2AP启动子的重组报告质粒.转染HEK-293T细胞,行荧光素酶活性检测,计算相对活性单位(RLU).生物信息学分析转录因子结合位点.结果 酶切,测序鉴定证实成功构建含有CD2AP基因转录起始位点上游2082 bp的启动区的表达质粒.CD2AP的启动子与正常的pGL-3基本质粒比较,其RLU增加了74.8倍.其上游启动子区序列中含多个转录因子结合序列如AP1、Sp1、CREB和GATA-1等.结论 CD2AP转录起始位点上游序列在HEK-293T细胞中具有较强的启动活性.  相似文献   

10.
目的构建E2F1基因真核表达质粒,并初步探讨E2F1对CD2相关蛋白(CD2AP)启动子的作用。方法 RT-PCR扩增E2F1基因,构建含E2F1基因的重组真核表达质粒,重组质粒转染人胚肾HEK-293细胞。Western blot检测E2F1蛋白表达;双荧光素酶报告基因检测E2F1过表达后人CD2AP启动子的活性。结果核酸序列分析及Western blot结果证实,成功构建含E2F1基因的重组真核表达质粒;过表达E2F1能增强CD2AP启动子的活性。结论 E2F1编码基因在HEK-293细胞中获得正确表达,且E2F1蛋白可促进人CD2AP启动子的转录活性。  相似文献   

11.
Chondroitin sulfate proteoglycan (CSPG) inhibits neurite outgrowth of various neuronal cell types, and CSPG-associated inhibition of neurite outgrowth is mediated by the Rho/ROCK pathway. Mesenchymal stromal/stem cells (MSCs) have the potential to differentiate into neuron-like cells under specific conditions and have been shown to differentiate into neuron-like cells by co-treatment with the ROCK inhibitor Y27632 and the hypoxia condition mimicking agent CoCl2. In this study, we addressed the hypothesis that a ROCK inhibitor might be beneficial to regenerate neurons during stem cell therapy by preventing transplanted MSCs from inhibition by CSPG in damaged tissues. Indeed, dose-dependent inhibition by CSPG pretreatment was observed during morphological changes of Wharton’s jelly-derived MSCs (WJ-MSCs) induced by Y27632 alone. The formation of neurite-like structures was significantly inhibited when WJ-MSCs were pre-treated with CSPG before induction under Y27632 plus CoCl2 conditions, and pretreatment with a protein kinase C inhibitor reversed such inhibition. However, CSPG treatment resulted in no significant inhibition of the WJ-MSC morphological changes into neuron-like cells after initiating induction by Y27632 plus CoCl2. No marked changes were detected in expression levels of neuronal markers induced by Y27632 plus CoCl2 upon CSPG treatment. CSPG also blocked the morphological changes of human bone marrow-derived MSCs into neuron-like cells under other neuronal induction condition without the ROCK inhibitor, and Y27632 pre-treatment blocked the inhibitory effect of CSPG. These results suggest that a ROCK inhibitor can be efficiently used in stem cell therapy for neuronal induction by avoiding hindrance from CSPG.  相似文献   

12.
13.
Rationale The role of Rho/Rho-associated kinase (ROCK) in regulating dendritic and axonal morphology during development has gained much attention. Very little is known, however, about the role of the Rho/ROCK pathway in emotional behavior.Objective To investigate the role of ROCK in emotional behaviors. We examined how the ROCK inhibitor Y27632 affects the performance of mice on three behavioral tests that measure anxiety-related behaviors.Results In the elevated plus-maze test, Y27632 (10 nmol, intracerebroventricular) induced a significant decrease in the percentage of time spent in the open arms and in the percentage of entries into open arms. In the fear conditioning test, Y27632-treated mice froze significantly more often and longer than did saline-treated mice. In the hole-board test, Y27632 significantly suppressed head-dipping behavior in Y27632-treated mice than in saline-treated mice. On the other hand, Y27632 did not produce on spontaneous alteration performance in the Y-maze test. These results indicate that ROCK inhibition increased anxiety-related behaviors.Conclusion Our findings suggest that the ROCK pathway is involved in the expression of anxiety- and fear-related behaviors. Furthermore, we propose that if the Rho/ROCK pathway plays an important role in mediating anxiety-related behaviors in humans, it may prove to be a novel system for anxiolytics to target.  相似文献   

14.
目的 研究Rho激酶抑制剂Y27632对脓毒症大鼠肠屏障功能障碍的影响及机制.方法 SD大鼠分为4组:假手术组、Y27632对照组、模型组、实验组,每组8只.以盲肠结扎穿孔法建立脓毒症大鼠模型,假手术组和Y27632对照组只进行开腹手术而不进行盲肠结扎和穿孔;Y27632对照组和实验组造模前15 min腹腔注射Y276...  相似文献   

15.
16.
Proliferation of vascular smooth muscle cells stimulated by reactive oxygen species (ROS) may play a pivotal role in the pathogenesis of atherosclerosis. To clarify mechanisms by which ROS promote vascular atherogenesis, effects of fluvastatin, amlodipine, ozagrel (thromboxane synthetase inhibitor), GF109203X (a protein kinase C inhibitor) and Y27632 (a ROCK inhibitor) on the proliferation of guinea-pig basilar artery smooth muscle cells (GBa-SM3) in a 5% FBS culture medium were studied over 3 d in the presence or absence of a free radical scavenger, edaravone. Viability of cells at the end of incubation was measured by the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) test. Results demonstrated that fluvastatin and amlodipine by themselves possess antiproliferative effects on the GBa-SM3 cells at 10-100 microM and 0.1-1 microM, respectively. While edaravone possessed no antiproliferative effect by itself at 100 microM, it significantly (p<0.05) augmented the antiproliferative effects of fluvastatin and amlodipine. In addition, ozagrel, GF109203X and Y27632 possessed no appreciable effects on the cell growth by themselves. However, coincubation of edaravone at 100 microM with these agents elicited significant antiproliferative effects for ozagrel, GF109203X and Y27632 at 10-100 microM, 1-10 microM and 0.1-1 microM, respectively. In conclusion, edaravone may have clinically beneficial interactions with fluvastatin, amlodipine and ozagrel regarding the prevention of vascular atherosclerosis. The interactions between edaravone and the inhibitors of protein kinase C and ROCK were suggestive of possible contributions of ROS-triggered intracellular signals associated with these enzymes to vascular atherogenesis, but further studies are required for confirmation.  相似文献   

17.

Background and Purpose

Combretastatin A-4 3-O-phosphate (CA4P) is in clinical trial as a tumour vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear. We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the effects of this drug in vivo.

Experimental Approach

Mouse models of human colorectal carcinoma (SW1222 and LS174T) were used. Effects of the ROCK inhibitor, Y27632, alone or in combination with CA4P, on ROCK activity, vascular function, necrosis and immune cell infiltration in solid tumours were determined. Mean arterial BP (MABP) was measured to monitor systemic interactions and the vasodilator, hydralazine, was used to control for the hypotensive effects of Y27632.

Key Results

Y27632 caused a rapid drop in blood flow in SW1222 tumours, with recovery by around 3 h, which was paralleled by MABP changes. Y27632 pretreatment reduced CA4P-induced ROCK activation and partially blocked CA4P-induced tumour vascular effects, in both tumour types. Y27632 also partially inhibited CA4P-induced tumour necrosis and was associated with reduced immune cell infiltration in SW1222 tumours. Hydralazine caused a similar hypotensive effect as Y27632 but had no protective effect against CA4P treatment.

Conclusions and Implications

These results demonstrate that ROCK activity is critical for full manifestation of the vascular activity of CA4P in vivo, providing the evidence for pharmacological intervention to enhance the anti-tumour efficacy of CA4P and related VDAs.  相似文献   

18.
PURPOSE: Tubulointerstitial fibrosis is a final common pathway to end-stage chronic kidney diseases, which are characterized by elevated renal angiotensin II (AngII) production. This peptide participates in kidney damage inducing fibrosis and epithelial mesenchymal transition (EMT). Our aim was to describe potential therapeutic targets in AngII-induced EMT, investigating the blockade of different intracellular pathways. METHODS: Studies were done in human tubular epithelial cells (HK2 cell line), evaluating changes in phenotype and EMT markers (Western blot and immunofluorescence). RESULTS: Treatment of HK2 cells with AngII for 3 days caused transdifferentiation into myofibroblast-like cells. The blockade of MAPKs cascade, using specific inhibitors of p38 (SB203580), extracellular signal-regulated kinase1/2 (ERK; PD98059) and Jun N-terminal kinase (JNK) (SP600125), diminished AngII-induced EMT. The blockade of RhoA/ROCK pathway, by transfection of a RhoA dominant-negative vector or by ROCK inhibition with Y-27632 or fasudil, inhibited EMT caused by AngII. Connective tissue growth factor (CTGF) is a downstream mediator of AngII-induced EMT. MAPKs and ROCK inhibitors blocked CTGF overexpression induced by AngII. HMG-CoA reductase inhibitors, although blocked AngII-mediated kinases activation, only partially diminished EMT and did not regulate CTGF. CONCLUSIONS: These data suggest a potential therapeutic use of kinase inhibitors in renal fibrosis.  相似文献   

19.
Tan H  Zhong Y  Shen X  Cheng Y  Jiao Q  Deng L 《Neuropharmacology》2012,63(6):1182-1190
We investigated whether the RhoA/ROCK pathway was involved in the effect of erythropoietin (EPO) to promote retinal ganglion cells (RGCs) axonal regeneration in a rat optic nerve crush (ONC) model. We demonstrated that both EPO and ROCK inhibitor Y-27632 significantly enhanced RGCs survival and axon regeneration in vivo, and the effects of these agents were additive. Expression of active-RhoA was decreased after EPO or Y-27632 per pull down assay and affinity precipitation. Administration of EPO and Y-27632 cocktail resulted in even more RhoA inactivation, decreased expression of ROCK-1 and ROCK-2, and increased expression of growth associated protein-43 (GAP-43) protein per immunohistochemistry and western blot analysis. Down-regulation of active-RhoA, ROCK-1, and ROCK-2 expression by EPO coincided with the appearance of larger numbers of regenerating axons. In conclusion, the RhoA/ROCK signaling pathway was involved in the EPO effect to promote RGCs axon regeneration after ONC.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号